Jacobs Levy Equity Management’s Filana Therapeutics FLNA Stock Holding History

Jacobs Levy Equity Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$353K	Sell	209,080 -37,907	-15%	-$78K	﹤0.01%	866
2025 Q4	$489K	Buy	246,987 +22,329	+10%	+$71.5K	﹤0.01%	799
2025 Q3	$654K	Buy	+224,658	New	+$517K	﹤0.01%	781
2015 Q1	–	Sell	-1,829	Closed	-$26K	–	862
2014 Q4	$26K	Buy	+1,829	New	+$31.7K	﹤0.01%	804

Other funds holding FLNA

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Jacobs Levy Equity Management's FLNA Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Filana Therapeutics (FLNA) stake by 15% in Q1 2026, selling an estimated $78K and leaving 209,080 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Jacobs Levy Equity Management first reported a position in FLNA in Q4 2014 and has held it in 4 quarters since. The position peaked at $654K in Q3 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

Jacobs Levy Equity Management held 209,080 shares of Filana Therapeutics worth $353K as of Q1 2026.
Jacobs Levy Equity Management sold 37,907 Filana Therapeutics shares in Q1 2026, an estimated $78K.
Filana Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #866 holding.
Jacobs Levy Equity Management first reported a position in Filana Therapeutics in Q4 2014 and has held it in 4 quarters since.
Jacobs Levy Equity Management's Filana Therapeutics position peaked at $654K in Q3 2025.
101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.